ABL2 (also known as ARG (ABL related gene)) is closely related to the well-studied Abelson
kinase cABL. ABL2 is involved in human neoplastic diseases and is deregulated in solid …

ABL2/ARG (ABL-related gene) belongs to the ABL (Abelson tyrosine-protein kinase) family
of tyrosine kinases. ARG plays important roles in cell morphogenesis, motility, growth and …

A new SRC-Abl dual inhibitor, BMS354825, has recently been presented as a possible tool
to overcome resistance to imatinib in neoplasias caused by oncogenic variants of the …

Background: After the approval of imatinib, more than 25 antitumor agents targeting kinases
have been approved, and several promising candidates are at various stages of clinical …

Chronic myeloid leukemia (CML) is a stem cell disorder caused by a constitutively activated
tyrosine kinase, the BCR-ABL oncoprotein. Imatinib (STI571, Gleevec) is a small-molecule …

Imatinib (Gleevec) is currently the frontline therapy for chronic myeloid leukemia (CML), a
disease characterized by the presence of a constitutively activated chimeric tyrosine kinase …

We present a high-resolution (2.0 Å) crystal structure of the catalytic domain of a mutant
form of the Abl tyrosine kinase (H396P; Abl-1a numbering) that is resistant to the Abl …

There is still a great demand in the clinic for the drugs which can overcome a variety of
imatinib resistant ABL mutants. Starting from a type I inhibitor axitinib, which has been …

Abelson (Abl) tyrosine kinase is an important cellular enzyme that is rendered constitutively
active in the breakpoint cluster region (BCR)-Abl fusion protein, contributing to several forms …

Chronic myeloid leukemia (CML) is caused by the constitutively activated tyrosine kinase
breakpoint cluster (BCR)-ABL. Current frontline therapy for CML is imatinib, an inhibitor of …